Edesa Biotech (EDSA) Net Income (2013 - 2026)
Edesa Biotech (EDSA) posted Net Income of -$2.4 million for Q4 2025, down 0.6% sequentially from -$2.4 million in Q3 2025, and down 22.24% YoY from -$3.1 million in Q4 2024.
Edesa Biotech (EDSA) Net Income (2013 - 2026) Analysis & Trends
Edesa Biotech has reported Net Income for 13 years, with the latest figure at -$2.4 million in Q4 2025.
- Quarterly Net Income fell 22.24% year-over-year to -$2.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$8.2 million (down 23.72% YoY) and the FY2025 annual result came in at -$7.4 million, down 16.92% from the prior year.
- Net Income retreated to -$2.4 million in Q4 2025 per EDSA's latest filing, from -$2.4 million in the prior quarter.
- Over five years, Net Income peaked at $1.8 million in Q3 2022 and troughed at -$5.8 million in Q2 2022.
- A 5-year average of -$2.5 million and a median of -$2.2 million in 2021 frame the typical range for Net Income.
- The sharpest annual moves came in 2022 and 2023: Net Income jumped 1330.9% in 2022, then tumbled 212.08% in 2023.
- Over 5 years, Net Income stood at -$5.3 million in 2021, then grew by 21.93% to -$4.1 million in 2022, then climbed by 15.44% to -$3.5 million in 2023, then jumped by 42.43% to -$2.0 million in 2024, then slipped by 22.24% to -$2.4 million in 2025.
- According to Business Quant data, Net Income over the past three periods registered -$2.4 million, -$2.4 million, and -$1.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Edesa Biotech | 40.44 Mn | 40.44 Mn | - | -5.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.41 Mn |
| Dec 31, 2025 | -2.44 Mn |
| Sep 30, 2025 | -2.43 Mn |
| Jun 30, 2025 | -1.75 Mn |
| Mar 31, 2025 | -1.59 Mn |
| Dec 31, 2024 | -2.00 Mn |
| Sep 30, 2024 | -1.11 Mn |
| Jun 30, 2024 | -1.67 Mn |
| Mar 31, 2024 | -1.86 Mn |
| Dec 31, 2023 | -3.47 Mn |
| Sep 30, 2023 | -2.06 Mn |
| Jun 30, 2023 | -1.98 Mn |
| Mar 31, 2023 | -2.33 Mn |
| Dec 31, 2022 | -4.10 Mn |
| Sep 30, 2022 | 1.84 Mn |
| Jun 30, 2022 | -5.79 Mn |
| Mar 31, 2022 | -4.57 Mn |
| Dec 31, 2021 | -5.26 Mn |
| Sep 30, 2021 | -149,241.00 |
| Jun 30, 2021 | -4.76 Mn |